Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Next Previous
Trial Profile

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Esomeprazole (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Acronyms The BIO-GIO study

Most Recent Events

  • 01 Nov 2022 Primary endpoint (To evaluate the area under the curve of afatinib compared to afatinib concomitantly used with esomeprazole and to afatinib used with esomeprazole 3 hours prior in patients with non-small cell lung cancer.) has not been met, according to Results published in the Biomedicine and Pharmacotherapy.
  • 01 Nov 2022 Results published in the Biomedicine and Pharmacotherapy
  • 21 Jul 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top